For instance, an IgG1-based bispecific targeting CD20 and CD89 effectively recruited and activated CD89-positive neutrophils and macrophages to CD20-positive cancer cells, yielding prominent in vitro and in vivo anticancer activity [148,149]. This evidence concerns the gene FCAR and cancer.